

# D-AP5

# Catalog No: tcsc0020421

Available Sizes

Size: 5mg

Size: 10mg

**Specifications** 

CAS No:

79055-68-8

#### Formula:

 $C_5H_{12}NO_5P$ 

Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling

#### **Target:**

iGluR;iGluR

#### Purity / Grade:

>98%

#### Solubility:

10 mM in DMSO H2O : 50 mg/mL (ultrasonic);Ethanol : 2 mg/mL (ultrasonic)

#### **Alternative Names:**

D-APV;D-2-Amino-5-phosphonovaleric acid

#### **Observed Molecular Weight:**

197.13

### References

[1]. R H Evans, et al. The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant

Copyright 2021 Taiclone Biotech Corp.



amino acid-induced responses in isolated spinal cord preparations. Br J Pharmacol. 1982 Jan;75(1):65-75. [2]. Davis S, et al. The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J Neurosci. 1992 Jan;12(1):21-34. [3]. Morris RG, et al. N-methyl-d-aspartate receptors, learning and memory: chronic intraventricular infusion of the NMDA receptor antagonist d-AP5 interacts directly with the neural mechanisms of spatial learning. Eur J Neurosci. 2013 Mar;37(5):700-17.

## **Product Description**

D-AP5 is a **NMDA** receptor antagonist.

#### IC50 & Target: NMDA<sup>[1]</sup>

*In Vivo:* D-AP5 is a NMDA receptor antagonist. Chronic intraventricular infusion of D-AP5 causes a parallel dose-dependent impairment of spatial learning and long-term potentiation (LTP) *in vivo*. Intracerebral concentrations of D-AP5 fail to induce any measurable sensorimotor disturbance when spatial learning is prevented<sup>[1]</sup>. D-AP5 infusion is associated with a progressive reduction in swim speed over trials. D-AP5 causes sensorimotor disturbances in the spatial task, but these gradually worsened as the animals fail to learn. Rats treated with D-AP5 show a delay-dependent deficit in spatial memory in the delayed matching-to-place protocol for the water maze<sup>[2]</sup>.

D-AP5 infusion is associated with a progressive reduction in swim speed over trials. D-AP5 causes sensorimotor disturbances in the spatial task, but these gradually worsened as the animals fail to learn. Rats treated with D-AP5 show a delay-dependent deficit in spatial memory in the delayed matching-to-place protocol for the water maze[3].





All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.